⚡ Flash Summary

Highnoon Laboratories has announced a board meeting scheduled for October 28th, 2025, to approve the un-audited financial statements for the 3rd Quarter ending September 30, 2025. In compliance with PSX Regulations, the company has declared a closed period from October 21st to October 28th, 2025, restricting directors, CEOs, and executives from dealing in the company’s shares during this time. This announcement indicates the imminent release of the company’s financial performance for the quarter, which could influence investor sentiment and stock valuation. Investors should watch for the results of the upcoming board meeting.

📌 Key Takeaways

• 🗓️ Board Meeting: Highnoon Laboratories will hold a board meeting on October 28th, 2025.
• 🕒 Time: The meeting is scheduled for 11:00 a.m.
• 🏢 Location: The meeting will be held at the corporate office in Lahore.
• 📑 Agenda: The board will consider and approve un-audited financial statements for Q3 2025.
• 📊 Quarter End: The financial statements are for the quarter ended September 30, 2025.
• 🔒 Closed Period: A closed period has been declared from October 21st to October 28th, 2025.
• 🚫 Trading Restriction: Directors, CEOs, and executives are restricted from trading shares during the closed period.
• 📜 PSX Regulations: The closed period is required under 5.6.4 of PSX Regulations.
• 💼 Senior Management: Baqar Hasan, Senior General Counsel & Company Secretary, signed the announcement.
• ✉️ Copy To: The announcement was copied to The Executive Director, Corporate Supervision Department, and Securities and Exchange Commission of Pakistan.
• 📍 Registered Office: The registered office is located at 17.5 KM, Multan Road, Lahore.
• 🏢 Corporate Office: The corporate office is at Tricon Corporate Center, Jail Road, Lahore.
• 🌐 Website: Additional information can be found at www.highnoon-labs.com.
• 📞 Contact: Contact details include phone and fax numbers listed on the announcement.
• 📧 Email: Inquiries can be sent to info@highnoon.com.pk.

🎯 Investment Thesis

HOLD. Given the lack of specific financial information, a HOLD recommendation is appropriate. The upcoming release of the Q3 2025 financial statements will provide more clarity. A neutral stance is maintained until the financial results are analyzed. Price Target: To be determined after Q3 results. Time Horizon: Short-term, pending Q3 results.